ClinicalTrials.gg
RecruitingNCT05000996Updated Nov 9, 2026

Gut Microbiota in Metabolic Surgery

An observational study in Bariatric Surgery Candidate, Cardiovascular Diseases and Type 2 Diabetes, sponsored by Vanderbilt University Medical Center. Recruiting at 1 site in United States. Open to participants aged 21 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-09.

Primary conditionHypertensionRegistry: Cardiovascular DiseasesReclassifiedWhy we changed it
Registry
Cardiovascular Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Hypertension
Why
  1. The study's listed conditions name Hypertension, a narrower term within Cardiovascular Diseases.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Vanderbilt University Medical Center · Observational

How we know

From the registry’s dates

  • Started Aug 2021; still recruiting 5 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
300
Ages
21 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Hypertension by Vanderbilt University Medical Center — 8 open to participants now, 8 under way, none of them phase 3. Hypertension · Vanderbilt University Medical Center.

Started
2021
with 3 others
Observational
4 of 23
2 open now
Registered
15th of 23
by date

Among the 23 studies in Hypertension by Vanderbilt University Medical Center, this one is one of 4 that started in 2021, is one of 4 observational ones, and was the 15th registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

8 of the 23 studies in Hypertension by Vanderbilt University Medical Center are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 21 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Hypertension by Vanderbilt University Medical Center, or all of them as a file.
02

Study summary

Metabolic surgery is an emerging option to treat obesity-related metabolic diseases (e.g., type 2 diabetes) and prevent cardiovascular disease (CVD). Metabolic surgery can profoundly alter the gut microbiota; meanwhile, gut microbiota may affect surgical outcomes. Longitudinal studies that examined pre- to post-surgery changes in gut microbiota and its relation to cardiometabolic health after surgery are limited. Furthermore, few studies have included African Americans, a population with high rates of cardiometabolic diseases. The investigators aim to fill these research gaps by establishing a longitudinal, observational study of metabolic surgery patients and applying multi-omics to identify stool, blood, and/or tissue microbial features related to post-surgery cardiometabolic outcomes. In the current study, the investigators plan to enroll up to 300 patients who undergo metabolic surgery at Vanderbilt University Medical Center and follow them for up to 10 years after surgery. Fasting blood and stool samples will be collected at pre-surgery and 3-month, 1-year, 2-year, and 3-year post-surgery clinical visits. Tissue samples (e.g., biopsies of the liver and adipose and remnants of the stomach) will be collected during operation. Meanwhile, participants will complete a REDCap survey at baseline and 1-year, 2-year, and 3-year post-surgery. Participants' electronic medical records will be used to obtain additional information and facilitate long-term follow-up. The investigators will evaluate pre- to post-surgery changes in the fecal microbiome and fecal and blood levels of metabolites and proteins and the associations of microbiome, metabolites, and proteins with cardiometabolic improvements after surgery. This study will advance our understanding of the role of gut microbiota in metabolic surgery, which may translate into novel approaches to identify and treat obese patients for better cardiometabolic health.

03

Conditions studied

  • Bariatric Surgery Candidate
  • Cardiovascular Diseases
  • Type 2 Diabetes
  • Dyslipidemias
  • Hypertension
  • Morbid Obesity
04

In context

Hypertension Reclassified

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

This study's planned enrollment of 300 is below the median of 352 across 1,166 observational studies indexed under Hypertension.

Browse Hypertension studies →

Lead sponsor

Vanderbilt University Medical Center is the lead sponsor of 837 studies on the registry; 157 are open to participants now.

Of its 126 completed or terminated interventional studies of FDA-regulated products, 92 (73%) have results posted.

Compared within Hypertension, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Cardiovascular Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
21 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

We plan to enroll 300 patients who undergo metabolic surgery at the Vanderbilt University Medical Center and follow them up to 10 years after surgery

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be approved and scheduled for metabolic surgery at the Vanderbilt University Medical Center
  • Have a history of type 2 diabetes, hypertension, or dyslipidemia
  • Be able and willing to provide personal information and biological samples needed for the study

Exclusion criteria

Exclusion Criteria:

  • Prior gastric operations
  • A history of coronary artery disease, stroke, heart failure, infection, or untreated viral hepatitis
  • Chemotherapy or radiotherapy for cancer within 2 years
  • Current inflammatory bowel disease or celiac disease
  • Vomiting, constipation, or diarrhea within 7 days or use of antibiotics within 2 months
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
300 participants (estimated)
Target follow-up
10 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Interventions

  • ProcedureBariatric Surgery

    Roux-en-Y gastric bypass (RYGB) and vertical sleeve gastrectomy (VSG)

07

What researchers measure

Primary outcomes

  1. Estimated 10-year risk of atherosclerotic cardiovascular disease

    The 10-year risk of atherosclerotic cardiovascular disease based on the American College of Cardiology/American Heart Association pooled cohort equations, incorporating age, sex, race, systolic blood pressure, total cholesterol, HDL cholesterol, diabetes status, hypertension status, and smoking

    Time frame: From before surgery to 1 to 3-year after surgery to 10-year after surgery

Secondary outcomes

  1. Glycated hemoglobin

    Time frame: From before surgery to 1 to 3-year after surgery to 10-year after surgery

  2. Blood pressure

    Time frame: From before surgery to 1 to 3-year after surgery to 10-year after surgery

  3. Blood cholesterol

    Total, low-density, and high-density lipoprotein cholesterol

    Time frame: From before surgery to 1 to 3-year after surgery to 10-year after surgery

  4. Blood inflammatory proteins

    high-sensitivity C-reactive protein

    Time frame: From before surgery to 1 to 3-year after surgery to 10-year after surgery

08

Study locations

1 of 1 sites recruiting
  • Vanderbilt_University MC
    Nashville, Tennessee 37232, United States
    Recruiting
09

References and documents

Publications

  • Yu D, Shu XO, Howard EF, Long J, English WJ, Flynn CR. Fecal metagenomics and metabolomics reveal gut microbial changes after bariatric surgery. Surg Obes Relat Dis. 2020 Nov;16(11):1772-1782. doi: 10.1016/j.soard.2020.06.032. Epub 2020 Jun 27. PubMed 32747219 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2021 (actual). Primary completion is estimated for Dec 2028, 88 months after the start.

Of 348 non-industry observational studies under Hypertension, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 111. This study's planned 88 months is above that.

Counting every sponsor, half of 429 studies reached it within 38 months; a quarter within 17 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 2, 2021
First posted
Aug 11, 2021
StartActual
Aug 19, 2021
Primary completionEst.
Dec 31, 2028
CompletionEst.
Jan 1, 2035
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05000996
Responsible party
Danxia Yu (Associate Professor of Medicine, Vanderbilt University Medical Center) — Principal investigator
First posted
Aug 11, 2021
Start date
Aug 19, 2021
Primary completion
Dec 31, 2028 (estimated)
Completion
Jan 1, 2035 (estimated)
Last update
Nov 9, 2026

Study contacts

Danxia Yu, PhD
Contact
danxia.yu@vumc.org
615-936-7389
Charles R Flynn, PhD
Contact
robb.flynn@vumc.org
615-343-8329

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion